Дізнайтеся про найкращі ціни та клініки з лікування десмоїдної фіброми у Ізраїлі у 2026 році

Desmoid tumors are benign because they do not metastasize to distant organs. They are locally aggressive and invade nearby tissues. In Israel, the standard first-line management is active surveillance with MRI monitoring every 3 to 6 months. This approach prioritizes observation over immediate surgery.

• First-line approach: Active surveillance is favored for asymptomatic patients using periodic MRI scans.
• Regression rate: Approximately 20% to 30% of desmoid tumors shrink or stabilize spontaneously.
• Surgery criteria: Experts reserve surgery for rapid growth or threats to vital organ function.
• Recurrence risk: Post-surgical recurrence rates range from 25% to 60% due to infiltrative growth.
• Alternative therapies: Doctors use tyrosine kinase inhibitors or cryoablation when tumors progress during observation.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center report high success rates by utilizing multidisciplinary sarcoma boards. These boards often delay surgery in favor of targeted drug therapies. Data shows that clinics with JCI accreditation and Newsweek rankings provide more specialized oversight for these rare cases. Experienced surgeons like Dr. Almog Ben Yaacov focus on limb-sparing and function-preserving techniques when intervention becomes necessary.

Patient Consensus: Patients note that the term benign can be misleading because these tumors require lifelong monitoring. Many emphasize that a wait-and-see approach with regular imaging is less stressful than facing high recurrence risks after surgery.

Israel's leading desmoid tumor and sarcoma specialists include Prof. Ofer Merimsky at Sourasky Medical Center and Dr. Almog Ben Yaacov at Sheba Medical Center. These experts utilize multidisciplinary tumor boards to manage rare soft-tissue malignancies. Treatment centers in Tel Aviv report a 90% success rate for oncology cases.

• Surgical oncology expertise: Dr. Almog Ben Yaacov performs complex sarcoma resections and robotic procedures at Sheba.
• Advanced medical oncology: Prof. Ofer Merimsky leads the National Center for Bone and Soft Tissue Sarcomas.
• Interventional radiology: Specialists like Dr. Eldad Elnekave provide cryoablation and drug-eluting embolization for desmoids.
• Uro-oncology focus: Prof. Zohar Dotan manages genitourinary sarcomas at Sheba Medical Center using robotic techniques.

Bookimed Expert Insight: Israeli specialists prioritize organ-preserving techniques over aggressive surgery for desmoid tumors. Data shows centers like Sourasky Medical Center treat over 400,000 patients annually with a 90% oncology success rate. These high-volume institutions use joint tumor boards to prevent unnecessary surgeries. This collaborative approach is vital because desmoid tumors require precise, long-term monitoring rather than just immediate excision.

Patient Consensus: Patients emphasize finding a hospital with a dedicated sarcoma unit rather than choosing a solo surgeon. They note that getting a multidisciplinary team to review pathology is crucial for avoiding overtreatment.

Israel hosts several tertiary centers with specialized multidisciplinary sarcoma teams. These units integrate orthopedic oncologists, pathologists, and radiologists to manage bone and soft tissue tumors. Notable facilities include Sourasky Medical Center, Sheba Medical Center, and Hadassah University Medical Center. They utilize specialized tumor boards to determine treatment protocols.

• Sourasky Medical Center: Houses a recognized National Sarcoma Center for pediatric and adult cases.
• Sheba Medical Center: Features a Department of Sarcomas specializing in advanced limb-sparing procedures.
• Hadassah Medical Center: Provides comprehensive evaluations including advanced radiotherapy and multi-stage surgical reconstructions.
• Rambam Health Care Campus: Serves as the primary reference hub for sarcoma in Northern Israel.

Bookimed Expert Insight: Data shows that centers like Sheba Medical Center utilize surgeons with specific credentials from Memorial Sloan Kettering. For example, Dr. Almog Ben Yaacov and Dr. Zohar Dotan both completed fellowships there. This highlights a trend where Israeli sarcoma teams are led by specialists with high-volume experience from top US oncology institutions.

Patient Consensus: Patients emphasize that a multidisciplinary review often changes the initial treatment plan. They strongly recommend requesting a pathology re-review by a sarcoma expert before starting any treatment.

Israel offers a unique intra-arterial therapy for desmoid tumors called selective intra-arterial doxorubicin drug-eluting embolization. This specialized procedure targets the tumors blood supply directly. It delivers highly concentrated chemotherapy via microcatheters. This method minimizes systemic toxicity while effectively shrinking tumor mass.

• Procedure mechanic: Microscopic beads release doxorubicin directly into feeding arteries.
• Reduced toxicity: Concentrating drugs in the tumor prevents damage to the heart.
• Clinical results: Israeli center research shows 59% median tumor volume reduction.
• Symptom management: Rapid pain relief allows patients to reduce heavy medications.

Bookimed Expert Insight: Israeli medical centers like Sourasky (Ichilov) maintain a 90% oncology success rate. Our data indicates that patients choosing Israel often access protocols like drug-eluting embolization before considering radical surgery. This is vital for desmoid tumors in complex anatomical sites. These centers manage high volumes of over 400,000 patients yearly. This experience is critical for managing slow, uneven tumor responses correctly.

Patient Consensus: Patients value how this targeted infusion preserves tissue and function in difficult areas. Many note that while shrinkage is slow, the relief from pain and swelling is a major recovery milestone.

Israeli hospitals provide advanced non-surgical ablation therapies including cryoablation, high-intensity focused ultrasound (HIFU), and radiofrequency ablation (RFA). These precise technologies destroy abnormal tissues using extreme temperatures or electrical currents. Specialized centers also offer irreversible electroporation (NanoKnife) for tumors near sensitive structures like nerves or vessels.

• Cryoablation: Uses extreme cold from liquid nitrogen to freeze and destroy tumor cells.
• MRgFUS technology: Employs focused ultrasound waves to heat deep tissues without any skin incisions.
• Radiofrequency ablation: Uses high-frequency electrical currents to generate heat and neutralize target lesions.
• NanoKnife therapy: Applies high-voltage electrical pulses for non-thermal ablation near critical blood vessels.
• SBRT: Delivers concentrated radiation beams as a non-invasive tool for localized tissue destruction.

Bookimed Expert Insight: Israeli specialists often prioritize microwave and NanoKnife ablation for complex gastrointestinal or liver cases. Dr. Almog Ben Yaacov at Sheba Medical Center is specifically trained in these advanced modalities. This focused expertise is vital when tumors sit near major structures where traditional heat or cold might cause damage.

Patient Consensus: Patients often choose cryoablation over surgery to avoid functional loss or scarring from desmoid tumors. They recommend confirming the recovery plan as repeat sessions and post-procedure swelling are common during the shrinking process.

Systemic and targeted therapies for desmoid tumors include gamma-secretase inhibitors, tyrosine kinase inhibitors (TKIs), and cytotoxic chemotherapy. Specialists prescribe these when tumors grow rapidly or cause pain. Israeli oncology centers like Sourasky Medical Center utilize these protocols for cases failing active surveillance.

• Gamma-secretase inhibitors: Nirogacestat is the first FDA-approved targeted drug for progressing desmoid tumors.
• Tyrosine kinase inhibitors: Doctors prescribe oral TKIs like sorafenib and pazopanib to block tumor blood supply.
• Cytotoxic chemotherapy: Vinblastine or methotrexate regimens are used for symptomatic or anatomically critical tumors.
• Hormonal therapy: Anti-estrogen medications are sometimes used as secondary options for slowly growing cases.

Bookimed Expert Insight: While many clinics offer generic oncology care, choosing a center with a multidisciplinary tumor board is vital. Sheba Medical Center utilizes these boards to personalize systemic plans. Their experts, like Dr. Raanan Berger, specialize in molecular research. This ensures patients access the latest TKIs which are more specific than traditional chemotherapy.

Patient Consensus: Patients note that while NSAIDs are often the first low-toxicity step, targeted TKIs are usually what finally stop tumor growth. Many emphasize that side-effect management is essential for staying on these long-term medications.

Recovery after desmoid tumor treatment in Israel varies by the procedure performed. Surgical resection requires several weeks to months to heal. Minimally invasive therapies like cryoablation or HIFU involve brief two-day recovery windows. Systematic therapies focus on managing fatigue and gastrointestinal issues.

• Surgical recovery: Physical healing typically lasts several weeks to months for tissue stabilization.
• Rehabilitation focus: Israeli centers provide tailored physical and occupational therapy for mobility.
• Follow-up timing: Clinical visits and MRI scans occur every 3–6 months initially.
• Long-term surveillance: Annual checks continue past year five for lifelong recurrence monitoring.

Bookimed Expert Insight: Israeli oncology centers like Sourasky Medical Center (Ichilov) leverage massive patient volumes to refine rare tumor protocols. Their oncology department reports a 90% success rate. Specialists like Dr. Almog Ben Yaacov at Sheba Medical Center focus on complex sarcomas. Highly experienced surgeons typically transition patients to contrast-enhanced MRI for high-risk monitoring during the critical first three years.

Patient Consensus: Patients note that physical recovery often takes months rather than weeks. Many emphasize that the stress of waiting for the first follow-up MRI is often more difficult than the physical treatment itself.